XML 12 R57.htm IDEA: XBRL DOCUMENT v3.19.3
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Apr. 11, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2018
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenues             $ 866,863 $ 2,000,868   $ 3,832,442 $ 27,979,273  
Deferred grant funding             1,896,526     1,896,526   $ 4,165,848
AstraZeneca                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenues             255,000 1,800,000   3,000,000 4,500,000  
Collaborative Arrangement, Product | ApolloBio                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Territory expansion option period     3 years                  
Proceeds received in upfront payment         $ 19,400,000              
Upfront payment received         23,000,000       $ 23,000,000 23,000,000    
Advisory fees         960,000              
Additional revenue to be achieved                   $ 20,000,000    
Royalty period                   10 years    
Period from effective date for termination                   1 year    
Number of days written notice before termination                   90 days    
Collaborative Arrangement, Product | AstraZeneca                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Upfront payment received   $ 27,500,000       $ 27,500,000            
Anticipated development and regulatory event based payment receivable milestones                   $ 125,000,000    
Anticipated commercial event based payment receivable milestones                   115,000,000    
Number of additional products to be developed | product       2                
Deferred revenue             118,000     118,000    
Accounts receivable             122,000     122,000    
Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Collaborative agreement, funding to be received $ 56,000,000                      
Collaborative agreement, period to receive funding for research and development 5 years                      
Funding received for research and development             1,500,000 $ 1,200,000   4,600,000 $ 2,000,000  
Deferred grant funding             $ 829,000     $ 829,000    
Foreign Tax Authority | Collaborative Arrangement, Product | ApolloBio                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Foreign corporate income taxes reducing upfront payment         2,200,000              
Foreign non-corporate income taxes reducing upfront payment         $ 1,400,000